Skip to main content
. Author manuscript; available in PMC: 2022 Aug 15.
Published in final edited form as: Nat Genet. 2020 Oct 19;52(12):1283–1293. doi: 10.1038/s41588-020-00731-9

Extended Data Fig. 4. ACE2 and dACE2 expression across 10,185 tumors of 33 types in TCGA.

Extended Data Fig. 4

Based on RNA-seq read counts, ACE2-Ex1b is most expressed in kidney tumors—kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP). Most samples expressing dACE2-Ex1c are squamous tumors of head and neck (HNSC) and the lungs (LUSC). Based on a ≥ 5 reads/sample threshold, ACE2-Ex1a is expressed in 12.6%, ACE2-Ex1b – in 38.0% and dACE2-Ex1c—in 16.8% of all tumors.